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Abstract
Purpose The impact of visual acuity (VA) on Health-Related Quality of Life (HRQoL) and the cross-sectional and longitu-
dinal differences in HRQoL during the 11-year follow-up were investigated. The aim was to examine the impact declining 
vision has on HRQoL and to provide comparable data to facilitate the allocation of health-care resources.
Methods We utilized nationwide health examination surveys carried out by the National Institute for Health and Welfare 
in 2000 and 2011, providing a representative sampling of the Finnish adult population aged 30 and older. VA was assessed 
through Snellen E test, and HRQoL scores were evaluated using EQ-5D and 15D questionnaires. Multiple imputations with 
Markov chain Monte Carlo method was used to utilize the data more effectively. Regression analyses were conducted to 
assess the impact of declining VA on HRQoL, adjusted for incident comorbidities.
Results Lower VA status was associated with significantly lower HRQoL at both time points, most clearly observable below 
the VA level of 0.5. Declining VA resulted in statistically significant decline in HRQoL during the follow-up, greater with 
distance than near VA. 15D impairment associated with decline in the distance VA was also clinically meaningful and greater 
than that associated with any of the examined comorbidities.
Conclusions HRQoL was significantly and meaningfully impaired even before the threshold of severe vision loss or blindness 
was reached. The results encourage the improvement of available treatment options aiming to postpone the onset of visual 
impairment or declining VA, to maintain better quality of life among the population.
Keywords Quality of life · Visual acuity · Follow-up study · Population-based study · Epidemiology
Abbreviations
15D  15-Dimensional questionnaire assessing 
Health-Related Quality of Life
BDI  Beck Depression Inventory
EQ-5D  5-Dimensional questionnaire assessing 
Health-Related Quality of Life
HRQoL  Health-Related Quality of Life
LALES  The Los Angeles Latino Eye Study
MCIC  Minimum Clinically Important Change
NEI VFQ-25  The National Eye Institute Visual Function 
Questionnaire
QoL  Quality of Life
VA  Visual acuity
VRQoL  Vision-Related Quality of Life
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s1113 6-019-02260 -3) contains 
supplementary material, which is available to authorized users.
 * Joonas Taipale 
 joonas.taipale@tuni.fi
1 Faculty of Medicine and Health Technology, Department 
of Ophthalmology, University of Tampere, Tampere, Finland
2 Finnish Register of Visual Impairment, Finnish Federation 
of the Visually Impaired, Helsinki, Finland
3 National Institute for Health and Welfare, Helsinki, Finland
4 ESiOR Ltd, Kuopio, Finland
5 School of Pharmacy, University of Eastern Finland, Kuopio, 
Finland
6 Department of Neurobiology, Care Sciences and Society, 
Karolinska Institute, Stockholm, Sweden
7 Tays Eye Center, Tampere University Hospital, Tampere, 
Finland
3226 Quality of Life Research (2019) 28:3225–3236
1 3
Introduction
Vision plays a major role in maintaining the abilities 
needed in everyday life, such as learning, working capac-
ity, self-care, and mobility [1–3]. For instance, Gompel 
et al. report, that children with low visual acuity (VA) need 
more time for reading and comprehending text, while the 
comprehension skill itself does not differ from those with 
normal VA. [4] Impaired VA is associated with increased 
risk of accidents, particularly falling [5]. Along with main-
taining the functional ability, there is evidence suggesting 
poor vision increases the risk of institutionalization [6]. 
Declining vision also causes problems in different aspects 
of daily life, for instance, in social interactions and daily 
routines [7–9]. In Finland, visually impaired people have 
a lower level of education and employment on average, 
compared to the overall population [10].
Some of the other population-based studies previously 
conducted focusing on vision and declining VA are The 
Rotterdam Study [11], The Blue Mountain Eye Study 
[12], Korea National Health and Nutrition Examination 
Survey [13], Melbourne Visual Impairment Project [14], 
and The Beaver Dam Eye Study [15]. Being researched 
widely around the globe, none of these, however, include 
Health-Related Quality of Life (HRQoL) and analysis of 
its connection to declining VA.
Most of the previously conducted research on Quality of 
Life (QoL) and vision is highly focused only on the visually 
impaired or on specific eye diseases and their impact on QoL 
[16–18]. Therefore, they tend to be based on relatively small 
study populations that are not representative on a larger 
scale. Furthermore, eye diseases may also have an impact 
on QoL through other factors besides declining VA, such as 
potential adverse effects of medication, anxiety about the 
future, lost time and money spent on the diagnostics, thera-
peutic interventions, and follow-up, which may cause bias 
[19, 20]. To our knowledge, there is only one study investi-
gating the impact of declining visual function on HRQoL in 
general population—a longitudinal population-based study 
among Latino people [21], but the generalizability of these 
results into other ethnicities is currently unknown.
Correlation of declining VA and QoL has been studied 
to some extent using vision-specific QoL assessments, 
such as the Vision-Related Quality of Life (VRQoL) 
questionnaire [21, 22]. These instruments are considered 
highly condition specific [23], not allowing comparison 
across diseases and/or treatments. For generalizability and 
comparability, generic preference-based questionnaires 
are required. Quality of life measured through VRQoL—
questionnaire might also be influenced by non-visual fac-
tors [24]. Hence, it is important to contribute information 
about declining VA regardless of eye diseases.
In this study, we examined the profiles and the correlation 
of VA and self-reported HRQoL in Finnish adults in two 
time points in 2000 and 2011 using nationwide population-
based health surveys and generic preference-based HRQoL 
tools. This comprehensive approach allows us to get an 
overall perspective on QoL and how it is affected by vision 
loss. Using generic tools instead of vision-specific measures 
reduces the potential reporting bias associated with overem-
phasis of visual factors on the responders’ QoL.
Methods
Study population and survey design
We utilized data from two nationwide surveys of health and 
well-being carried out by the National Institute for Health 
and Welfare in 2000 and 2011. These Health 2000 and 
2011 studies provided a probability-clustered sampling and 
weighting scheme that estimates health statistics that are 
representative of Finnish adult population aged 30 and older 
at the time of sampling. The sampling scheme also accounts 
for designed oversampling among the elderly people in the 
2000 baseline. Our sample inclusively represents the Finn-
ish adult population with respect to main demographics 
of Finland. The general research methods have previously 
been described elsewhere in more detail [25, 26]. Briefly, the 
study participants were invited to participate in an interview 
and health examination in 2000, and in a follow-up survey 
in 2011. The demographics of study participants are sum-
marized in Table 1.
The mean age for those with complete data on VA was 
49.6 years in 2000 and 60.1 years in 2011 and the proportion 
of women was 55.3% (not shown in the table) in both time 
points, following quite well the general study population 
distributions
Visual acuity tests
Habitual distance VA was measured binocularly at 4 m, 
with current visual correction, using the Snellen eye chart. 
Habitual near VA was measured at the participant’s preferred 
reading distance, using the near vision chart. Illumination 
was set to ≥ 350 lx on the vision charts. [25, 26] All VA val-
ues are presented as decimal equivalents. For comparisons, 
the VA values were further classified based on forthcoming 
ICD-11 classification [27] and a priori judgement based on 
the clinical relevance of VA. VA ≥ 1.0 was classified as good 
vision, VA of 0.63–0.8 as adequate vision, VA ≤ 0.5 as weak 
vision, VA ≤ 0.25 as impaired vision, and VA < 0.1 as severe 
vision loss or blindness.
Habitual distance and near VA were measured at both 
time points (2000 and 2011). A change of at least two lines 
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on the Snellen eye chart was considered clinically significant 
improvement or decline, as smaller changes can be caused 
by numerous other factors, such as state of the tear film on 
ocular surfaces or preceding fatigue causing accommodative 
tiredness during the measurement [28–30].
Health‑Related Quality of Life assessment
HRQoL was assessed using two internationally established, 
generic and standardized preference-based questionnaires—
EQ-5D and 15D [31, 32]. Both methods yield a single index 
score, as well as a multidimensional profile. The EQ-5D 
has an answer scale ranging from 1 (no difficulties) to 3 
(extreme difficulty) and consists of five dimensions: mobil-
ity, self-care, usual activities, pain/discomfort, and anxiety/
depression. The 15D has an answer scale ranging from 1 
(no difficulties) to 5 (extreme difficulty) and comprises 15 
dimensions: mobility, vision, hearing, breathing, sleeping, 
eating, speech, excretion, usual activities, mental function, 
sexual activity, discomfort and symptoms, depression, dis-
tress, and vitality. For both methods, weighting the separate 
dimensions with population-based preference weights yields 
index scores ranging from 0 to 1 for 15D and from − 0.59 to 
1 for EQ-5D, with 1 representing the best possible HRQoL. 
In the present study, 15D was weighted using Finnish pref-
erence weights, whereas EQ-5D was weighted using UK 
time-trade-off weights in order to achieve the widest pos-
sible comparability [33]. Clinically meaningful difference 
can be defined as the least change health-care professionals 
or the study participants themselves may observe. In the 
present study, we used previously given thresholds of ≥ 0.07 
for EQ-5D and ≥ 0.015 for 15D as clinically meaningful dif-
ferences [34, 35].
For the examination of separate dimensions of EQ-5D, 
dimension level 1 was considered as “no difficulties” while 
reported level 2–3 resulted “difficulties” in such dimension. 
For 15D, the individual dimensions were converted to 0–1 
scale by applying the established Finnish multi-attribute 
utility weights. Validity, feasibility, and reliability of this 
method are further discussed in previous publication. [36] 
For brevity, only ‘Vision’ dimension of 15 total individual 
dimensions included in 15D was reported separately here in 
addition to 15D index scores.
HRQoL was evaluated in both time points (2000 and 
2011) to assess the changes during the follow-up period. 
Eye examination alongside the HRQoL assessment made 
it possible to evaluate the effect of declining vision on the 
quality of life.
Data analysis
The overall prevalence for distance and near VA grouped 
according to age was estimated by using population data at 
StatFin database (Statistics Finland). The data (collected and 
reported annually) were applied for both samples according 
to the investigation year.
Odds ratios for individual EQ-5D dimensions and corre-
lations between measured distance or near VA and HRQoL 
index scores were conducted implementing the Complex 
Samples module in IBM SPSS Statistics for Windows, ver-
sion 24 (IBM Corp., Armonk, N.Y., USA), to account for 
the complex sampling design. The analyses were adjusted 
for age, sex, and the most common comorbidities, specified 
below. P-values were adjusted with Bonferroni correction 
when making multiple comparisons. Changes in VA dur-
ing the follow-up period and its impact on HRQoL changes 
were estimated through linear regression with adjustments 
for new incident diagnoses of the comorbidities, as well as 
baseline HRQoL. Variance inflation factors (VIFs) were 
used to measure multicollinearity in regression analyses.
To utilize the data more effectively, multiple imputations 
method was used to handle missing comorbidities in the 
regression analyses concerning the longitudinal changes 
[37]. Missing data were predicted using respondent’s non-
missing data in five imputations applying iterative Markov 
chain Monte Carlo method [38]. After conducting the five 
imputations, the estimates of the variables with previously 
missing values were pooled to give single estimates to be 
utilized in the final analysis. Missing VA changes were not 
imputed.
Table 1  The demographics of 




2000 2011 Both time points
Sample size (% women) 8028 (54.7%) 8006 (53.0%) 4703 (55.5%)
Mean age (SD) 54.71 (16.2) 55.34 (15.6) 49.6 (12.1)a
60.0 (12.1)b
EQ-5D Index Score available 6148 4084 3131
15D index score available 6166 4266 3510
Distance VA measured 6674 4619 3867
Near VA measured 6646 4618 3860
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When comparing the data between the time points, the 
weighting scheme calculated by National Institute for Health 
and Welfare was applied to account for the intentional over-
sampling in 2000 time point as well as the loss to follow-
up. The sampling scheme is based on IPW-method (reverse 
probability), further discussed in the previous publications. 
[39, 40] Subgroups with minimum size of three participants 
were included in population analysis. Age distributions for 
both time points, taken from population statistics in the 
StatFin (Statistics Finland) database, were applied to better 
represent the impact of declining VA population-wise. Ken-
dall’s tau-B test and/or regression models were used when 
estimating the associations between continuous and ordinal 
variables.
Comorbidities
For most of the analyses, common diseases were consid-
ered to account for their potential impact on the HRQoL. 
The diseases were self-reported both in 2000 and 2011 and 
were classified to major comorbidity groups for robustness. 
Myocardial infarction, Angina Pectoris, heart failure, rhythm 
disorders, and “other heart disorder” were considered as 
“Heart diseases.” Asthma, chronic obstructive pulmonary 
disease (COPD), chronic bronchitis, and “other pulmonary 
disease” were categorized as “Pulmonary diseases.” “Vas-
cular diseases” included stroke and varicose veins in lower 
limbs. “Musculoskeletal conditions” included self-reported 
rheumatoid arthritis, arthrosis, fractures, and osteoporo-
sis. “Psychiatric diseases” consists of psychotic disorders, 
depression, anxiety, psychoactive substance abuse, or “other 
psychiatric disease.” In addition, hypertension, diabetes, Par-
kinson’s disease, and cancer (unspecified) were included in 
our model.
Study participant was considered to have comorbidity, if 
participant reported having any of the conditions included 
in the comorbidity group. When examining new incident 
diagnoses during the follow-up period, each condition was 
scrutinized in 2000 baseline and in 2011 follow-up. If study 
participant reported one or more new condition included 
in the given comorbidity group during 2011 follow-up, 
participant was classified as having incident comorbidity, 
regardless of the presence of other conditions included in 
that specific comorbidity group in baseline.
Results
Visual acuity in the study population
The proportion of participants with good VA decreased by 
age at both time points (Table 2). Average distance and near 
VA improved between the time points, and the age-, and sex-
adjusted prevalence of good distance and near VA increased. 
The cross-sectional correlation between the VA and HRQoL 
Table 2  Distance and near VA in different age groups in Health 2000 and 2011 studies
The prevalence is adjusted based on the weighting scheme of the National Institute for Health and Welfare. Different weights have been applied 
for 2000 and 2011 data to represent the Finnish population in each of these time points. Weighting is adjusted for age and sex, and also accounts 
for the loss between the time points
2000 2011
30–44 45–54 55–64 65–74 75+ All 30–44 45–54 55–64 65–74 75+ All
Distance vision, n 2210 1666 1124 842 832 6674 1039 1057 1160 850 513 4619
Women  % 52.9 51.3 53.5 56.8 70.6 55.2 57.4 55.0 52.8 55.5 59.3 55.5
Good  % (VA ≥ 1) 94.0 85.0 78.7 53.7 17.9 76.7 95.6 91.0 83.8 70.5 31.2 80.0
Adequate  % (VA 0.63–0.8) 4.4 12.0 16.5 34.0 39.9 15.7 3.5 7.3 12.4 23.3 43.2 14.4
Weak  % (VA 0.32–0.5) 1.5 2.8 4.3 9.9 29.4 6.0 0.8 1.4 2.8 4.6 19.7 4.3
Impaired  % (0.1–0.25) 0.1 0.1 0.4 1.8 8.3 1.1 0.2 0.2 0.8 1.1 4.3 1.0
Severe loss  % (VA < 0.1) 0.0 0.2 0.2 0.6 4.5 0.6 0.0 0.0 0.2 0.5 1.6 0.3
Average distance VA 1.16 1.09 1.03 0.88 0.58 1.01 1.19 1.14 1.08 0.99 0.74 1.07
Near vision (n) 2 210 1 661 1 118 838 819 6 646 1 039 1 055 1 160 849 515 4 618
Women  % 52.9 51.4 53.5 56.7 70.8 55.3 57.4 54.9 52.8 55.5 59.4 55.5
Good  % (VA ≥ 1) 86.4 54.5 56.3 42.7 18.8 60.8 90.0 63.7 61.9 53.3 28.7 64.3
Adequate  % (VA 0.63–0.8) 12.4 37.7 37.3 45.8 47.5 31.0 8.9 31.8 31.6 38.3 47.2 28.7
Weak  % (VA 0.32–0.5) 1.1 6.8 5.7 9.4 22.0 6.4 1.1 4.1 4.4 7.1 18.8 5.6
Impaired  % (0.1–0.25) 0.2 0.9 0.5 2.0 10.1 1.6 0.0 0.3 1.9 0.9 4.5 1.2
Severe loss  % (VA < 0.1) 0.0 0.1 0.2 0.0 1.5 0.2 0.0 0.0 0.2 0.5 0.8 0.2
Average near VA 1.14 0.92 0.92 0.84 0.63 0.95 1.16 0.99 0.96 0.91 0.75 0.99
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index values was strongest for VA below 0.5, as shown in 
our Supplementary Figs. S1 and S2.
Cross‑sectional association between vision 
and health‑related quality of life
The differences between study participants with good 
(VA ≥ 1.0) and weak distance vision (threshold of VA ≤ 0.5, 
LogMAR 0.3) were statistically significant (p < 0.001) with 
both EQ-5D (Fig. 1a) and 15D (Fig. 1b), suggesting that 
lower vision status associates with declining quality of life 
even before it reaches the threshold of visual impairment 
or blindness. The trends were similar for near vision, with 
statistically significant differences observed (p < 0.001) with 
both HRQoL instruments (Fig. 1c, d) and clinically mean-
ingful for 15D assessment results even in adequate VA group 
(Fig. 1b, d).
When considering the individual HRQoL dimensions, 
the most notable correlation with lower distance or near 
VA statuses was observed for mobility, self-care, and usual 
activities (Fig. 2). Interestingly, anxiety/depression EQ-5D 
dimension, while statistically significant, appeared to have 
only relatively weak association with lower VA groups.
After adjusting for sex, age, and multiple comorbidities, 
the increasing proportion of respondents reported difficul-
ties in every EQ-5D dimension except for pain/discomfort 
dimension with declining distance VA in 2000 (Table 3). 
Most of the Odds Ratios, compared to those with good VA, 
were also statistically significant. At the follow-up assess-
ment, the increasing odds were statistically significant only 
for usual activities dimension. The odds of having difficul-
ties especially in the EQ-5D dimensions of usual activities 
and self-care clearly increased compared to those with good 
VA, particularly when examining those with lower near VA 
(Table 4). The differences in associations between the time 
points were clearly visible in the dimensions of mobility and 
self-care, especially when examining correlation between 
near VA and these EQ-5D dimensions. In the study popu-
lation, having difficulties concerning anxiety/depression 
seemed to become prominent only when impairment or 
severe vision loss was observed. This was the case espe-
cially in 2000, when the odds for experiencing problems 
Fig. 1  Differences in Health-Related Quality of Life (HRQoL) index 
scores in relation to those with good habitual distance (a, b) and near 
(c, d) visual acuity (VA) in both time points. The y-axis represents 
the mean index value difference in relation to good VA (VA ≥ 1.0). 
The x-axis represents VA groups. Dashed line represents the minimal 
clinically important change (MCIC), 0.07 for EQ-5D and 0.015 for 
15D [34, 35]. The weighting scheme is applied to address the differ-
ences in study populations’ age and sex distributions and to allow the 
comparison between the time points. The mean HRQoL index values 
for good VA group were 0.87 for a, 0.93 for b, 0.88 in 2000, and 0.87 
in 2011 for c and 0.93 for d 
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were over threefold. In 2011, the impact of declined VA on 
anxiety/depression was statistically insignificant. In baseline, 
declined VA seemed to have a broader impact on the EQ-5D 
dimensions, having significant effect on four dimensions (all 
except pain/discomfort), while in 2011 only one dimension 
for distance VA (usual activities) and two dimensions for 
near VA (usual activities and self-care) were statistically sig-
nificantly affected. Usual activities were the EQ-5D dimen-
sion most strongly associated with declined VA. Being sta-
tistically significant in both time points for near and distance 
Fig. 2  The proportion of participants reporting difficulties in indi-
vidual EQ-5D dimensions, grouped according to visual acuity (VA). 
The x-axis represents EQ-5D dimensions for each VA group and the 
y-axis the proportion of participants reporting difficulties (answer-
ing 2 or 3 to a dimension). Correlations according to Kendall’s tau-B 
with their p values are shown for each dimension. All values pre-
sented are adjusted for sex and age
Table 3  The odds of having difficulties in EQ-5D dimensions compared to those in good distance visual acuity (VA ≥ 1.0) group
The Odds Ratios (with 95% CI) are estimated through SPSS complex samples logistic regression analysis adjusted with sex, age, and the fol-
lowing comorbidities: heart diseases, pulmonary diseases, vascular diseases, musculoskeletal conditions, psychiatric diseases, hypertension, dia-
betes, Parkinson’s disease, and cancer. p values, showing the trends, are adjusted with Bonferroni correction for multiple comparisons. Bolded 
values denote statistically significant (p < 0.05) odds ratios compared to good vision (VA ≥ 1.0)








1.173 (0.991–1.389) 1.217 (0.951–1.557) 1.474 (1.242–1.748) 1.141 (0.959–1.359) 1.051 (0.847–1.304)
Weak
0.32–0.5
1.670 (1.256–2.221) 2.240 (1.617–3.103) 2.044 (1.543–2.707) 0.910 (0.712–1.163) 1.287 (0.916–1.808)
Impaired or severe loss
≤ 0.25
2.805 (1.601–4.915) 6.612 (4.137–10.568) 9.149 (5.172–16.183) 0.967 (0.555–1.683) 3.625 (2.235–5.881)








1.436 (1.124–1.833) 1.712 (1.131–2.589) 1.757 (1.340–2.304) 1.237 (0.978–1.566) 1.539 (1.062–2.230)
Weak
0.32–0.5
1.604 (1.036–2.484) 2.280 (1.282–4.055) 1.297 (0.785–2.142) 1.192 (0.758–1.873) 1.937 (1.077–3.483)
Impaired or severe loss
≤ 0.25
2.100 (0.705–6.249) 3.223 (1.013–10.254) 8.702 (3.465–21.851) 1.109 (0.437–2.810) 2.525 (1.118–5.700)
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Table 4  The odds of having difficulties in EQ-5D dimensions compared to those in good near visual acuity (VA ≥ 1.0) group
The Odds Ratios (with 95% CI) are estimated through SPSS complex samples logistic regression analysis adjusted with sex, age, and the fol-
lowing comorbidities: heart diseases, pulmonary diseases, vascular diseases, musculoskeletal conditions, psychiatric diseases, hypertension, dia-
betes, Parkinson’s disease, and cancer. p values, showing the trends, are adjusted with Bonferroni correction for multiple comparisons. Bolded 
values denote statistically significant (p < 0.05) odds ratios compared to good vision (VA ≥ 1.0)








1.158 (0.991–1.354) 1.695 (1.325–2.167) 1.475 (1.255–1.735) 1.076 (0.956–1.210) 1.242 (1.021–1.510)
Weak
0.32–0.5
1.989 (1.491–2.652) 2.736 (1.922–3.894) 2.481 (1.838–3.348) 1.126 (0.869–1.460) 1.045 (0.696–1.570)
Impaired or severe loss
≤ 0.25
6.803 (3.863–11.980) 9.811 (6.161–15.622) 10.279 (5.923–17.839) 1.499 (0.861–2.612) 3.471 (2.014–5.980)








1.207 (0.991–1.470) 1.019 (0.712–1.459) 1.088 (0.840–1.408) 1.035 (0.885–1.210) 1.295 (0.940–1.785)
Weak
0.32–0.5
1.759 (1.185–2.611) 2.039 (1.078–3.857) 2.449 (1.589–3.775) 1.771 (1.179–2.660) 1.095 (0.621–1.932)
Impaired or severe loss
≤ 0.25
1.620 (0.755–3.477) 3.650 (1.410–9.453) 4.652 (2.249–9.622) 1.154 (0.530–2.515) 2.023 (0.740–5.533)
Table 5  Multivariable 
regression analysis examining 
the changes in EQ-5D and 15D 
index values between 2000 and 
2011
VA was considered improved or declined if difference of at least 2 lines in the Snellen eye chart was 
observed between the time points. The unstandardized B coefficients show the magnitude of the impact on 
HRQoL, while the standardized Beta coefficients allow the comparison of the explanatory variables with 
each other. Clinically meaningful B coefficients are bolded (≥ 0.07 for EQ-5D and ≥ 0.015 for 15D [34, 
35]). It should be noted that B regression coefficients represented in the table are independent and additive, 
meaning that if an individual experience a, e.g., decline in both near and distance VA, the HRQoL impacts 
of both need to be considered (added together)
*Denotes statistical significance with p < 0.05
**Denotes statistical significance with p < 0.001
Change in EQ-5D (n = 3068) Change in 15D (n = 3454)
B coefficients Beta coefficients B coefficients Beta coefficients
Constant 0.409** 0.272**
Male sex + 0.010 + 0.029 − 0.002 − 0.013
Incident heart disease − 0.032* − 0.054* − 0.015** − 0.065**
Incident pulmonary disease − 0.024* − 0.034* − 0.024** − 0.086**
Incident vascular disease − 0.013 − 0.017 − 0.013* − 0.043*
Incident musculoskeletal condition − 0.038** − 0.103** − 0.007* − 0.047*
Incident hypertension − 0.029** − 0.064** − 0.005 − 0.027
Incident diabetes − 0.014 − 0.020 − 0.017** − 0.061**
Incident psychiatric disorder − 0.060** − 0.069** − 0.024** − 0.070**
Incident Parkinson disease − 0.071 − 0.026 − 0.077** − 0.066**
Incident cancer − 0.021 − 0.028 − 0.012* − 0.041*
Change in Visual acuity (VA), 
compared to stable VA
 Distance VA declined − 0.062** − 0.090** − 0.033** −0.117**
 Distance VA improved − 0.028 − 0.027 + 0.000 + 0.000
 Near VA declined − 0.028* − 0.049* − 0.012* − 0.052*
 Near VA improved − 0.010 − 0.012 + 0.005 + 0.014
QoL index value in baseline − 0.473** − 0.427** − 0.293** − 0.312**
R2 0.197** 0.193** 0.132** 0.128**
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VA, it increases the OR to as high as tenfold comparing to 
those with good VA.
Changes in visual acuity and Health‑Related Quality 
of Life during 11 years
The results of the multivariable regression analysis exam-
ining the associations between changes in HRQoL index 
values and changes in VA are presented in Table 5. When 
adjusted for the incidence of common comorbidities, associ-
ation between decline in both distance VA and near VA was 
statistically significantly associated with declines in both 
EQ-5D and 15D over the 11-year study period, although the 
association with declining distance VA was greater than with 
declining near VA. Decline in distance VA was associated 
also with clinically meaningful decline in 15D. Findings did 
not change substantially, when only statistically significant 
(p < 0.05) factors were included as explanatory variables 
regression model in stepwise-insertion analysis (see Sup-
plementary Table S1). Multicollinearity was tested through 
VIFs (Variance inflation factors), which ranged from 1.007 
to 1.147 for the variables included in the models, denoting 
no or very little multicollinearity.
Newly diagnosed heart or pulmonary diseases were sta-
tistically significantly associated with the change in 15D 
vision dimension (Tables 6, S2). Naturally, declining near 
and distance VA also negatively affected the vision dimen-
sion value. The impact of declining distance VA seems to be 
somewhat greater than that of declining near VA. Interest-
ingly, improved VA did not have a statistically significant 
association with the change in 15D vision dimension.
Discussion
Visual acuity plays a major role in self-reported HRQoL, 
the threshold of 0.5 being notable. Subjects with VA below 
this threshold have greater and progressive decreases in their 
HRQoL. Functionally, the threshold of 0.5 in distance VA 
is relevant; as with current visual correction, it serves as the 
requirement for standard driving license in many states in 
the United States of America [41] and the countries of the 
European Union (directive 2006/126/EC), thereby affecting 
individual’s activities of daily living. Moreover, previous 
publication reports differences in self-care when VA is near 
the threshold of 0.5 (from 0.4 to 0.63) [42]. Our results point 
out that low vision correlates with low HRQoL. The impact 
of having lower VA is also clinically meaningful and does 
not impact only single dimension of the assessments applied.
The odds of having difficulties in individual EQ-5D 
dimensions become greater as VA is lower, which is the 
most evident in the areas of self-care and usual activities. 
Those with weak VA are more than twice as likely to experi-
ence problems in those two dimensions, possibly increasing 
the need for daily assistance, compared to those with good 
VA. With VA being impaired or study participants blind, the 
odds progressively accumulate to over tenfold.
Visual acuity plays a major role in self-reported HRQoL, 
especially in the dimensions of usual activities and self-care. 
The magnitude of association between EQ-5D dimensions 
associated and the lower VA status decreased between the 
time points. Especially, for mobility, the impact of low VA 
is evident in baseline, while in 2011 the impact is no longer 
statistically significant. During this period, improved mobil-
ity aids, such as the Segway Personal Transporter, electric 
travel aids including GPS-locating, and tactile gloves have 
been implemented, which might have contributed for those 
with vision loss not experiencing difficulties with mobility, 
self-care, and usual activities [43–46]. Moreover, voice-con-
trolled applications and devices have become routinely used. 
Environmental architecture and paying attention to acces-
sibility may also contribute to the improvement, although 
there are still many aspects that complicate usual activities 
for those with visual disability [46]. Observed improvement 
in anxiety/depression dimension of EQ-5D between the time 
points may be partly due to improvements in availability 
and accessibility of social services between 2000 and 2011.
Table 6  Regression analysis examining the change in 15D vision 
dimension between 2000 and 2011
VA was considered improved or declined if difference of at least 2 
lines in the Snellen eye chart was observed between the time points. 
Only the standardized Beta coefficients reported to allow the compar-
ison between the explanatory variables
Beta coefficients Sig.
Constant 0.685 < 0.001
Male sex − 0.014 0.344
Incident heart disease − 0.010 0.484
Incident pulmonary disease − 0.038 0.008
Incident vascular disease + 0.007 0.637
Incident musculoskeletal condition + 0.002 0.889
Incident hypertension − 0.025 0.094
Incident diabetes − 0.027 0.066
Incident psychiatric disorder − 0.004 0.801
Incident Parkinson disease − 0.016 0.248
Incident cancer − 0.006 0.693
Change in visual acuity (VA), compared 
to stable VA
 Distance VA declined − 0.190 < 0.001
 Distance VA improved − 0.008 0.553
 Near VA declined − 0.151 < 0.001
 Near VA improved − 0.004 0.788
15D Vision dimension value in baseline − 0.493 < 0.001
Adjusted R2 0.301 < 0.001
3233Quality of Life Research (2019) 28:3225–3236 
1 3
Low VA was associated with increased Anxiety/depres-
sion in the present study, and this has also been shown in 
previously conducted research [8, 47]. In our study, the 
impact of lower VA status in observed HRQoL became 
prominent only once vision was impaired or severely lost. 
While not in focus of the present study, in a supplemental 
analysis we examined the relation between anxiety/depres-
sion and measured VA, using Beck Depression Inventory 
(BDI), which purely concentrates on evaluating depression 
and mental well-being (see Supplementary Data). Unlike 
with anxiety/depression dimension of EQ-5D, where declin-
ing vision appears to have an impact only once vision is 
impaired or severely lost, BDI-scores and VA seem to have 
a linear connection. This promotes the endeavor to maintain 
visual function even before the onset of visual impairment. 
Due to the differences in questionnaires, EQ-5D is not as 
sensitive in identifying the early signs of anxiety/depression, 
applying also for 15D assessment. There may also be a psy-
chological explanation for this, which is related to the ques-
tion layout. In EQ-5D, the question about anxiety/depres-
sion is more straightforward with a limited answer scale, and 
study participants might not always identify depression and 
anxiety correctly. In BDI on the other hand, the subject is 
presented with a wide range of questions about the various, 
specific background factors contributing to depression, giv-
ing a more thorough analysis of the subject’s mental state.
The longitudinal findings from 15D assessment show 
similar changes in the index values. An important difference 
between 15D and EQ-5D assessments is that 15D includes a 
Vision dimension, which had a strong statistically significant 
association with declining VA in our analyses. Addition-
ally, the decline is more strongly associated with a decline 
in distance VA than with a decline in near VA. Overall, our 
findings emphasize the importance of maintaining good VA 
to prevent the incremental loss of HRQoL.
Both our results and those of The Los Angeles Latino 
Eye Study (LALES) indicate that HRQoL, while evaluated 
with different assessments, shows significant correlation 
to declining vision, suggesting that aging alone does not 
account for the decline in HRQoL [21]. The LALES-study, 
while being a population-based study, unfortunately had a 
follow-up time of only 4 years. As a result, there were only 
83 individuals whose VA declined in this time. These indi-
viduals appeared to have a slightly milder decrease (though 
statistically insignificant) in their general health (assessed 
via The National Eye Institute Visual Function Question-
naire (NEI VFQ-25)) when compared to those with stable 
VA. This is contrary to our findings, where declining VA 
caused decrease in HRQoL index values except for near VA 
applying EQ-5D assessment. For declining distance VA, 
HRQoL change assessed through 15D was also clinically 
meaningful. These findings may differ due to the differences 
in methods, follow-up time, study populations, or used 
HRQoL questionnaires.
The strengths of this study include a relatively long 
follow-up period of 11 years and a large study sample, 
which inclusively represents Finnish adult population aged 
30 or older. Being widely collected and comprehensive, 
our study population and design reduced the impact of 
confounding factors. In comparison to samples collected 
from health-care units, our data do not consist of specific 
patient groups, which is a major strength.
Previously conducted research in German population-
based sample confirms that VRQoL declines with age, 
assessed through NEI VFQ-25 questionnaire [22]. Their 
approach, however, lacks longitudinal perspective thereby 
making it difficult to exclude the impact of aging from 
other changes in society during the lifetime of different 
age groups. In our study, we took into account the effect 
of aging and common comorbidities, thus reducing their 
impact on the results.
As internationally established questionnaires were 
implemented in assessing the HRQoL, this study is com-
parable to previous and future research about conditions 
unrelated to vision. Questionnaire-based data collection 
represents the study participants’ perception of their eve-
ryday QoL. EQ-5D might not always be sensitive enough 
to show statistically significant changes as reported by 
Jones et al. [48]. However, when showing statistically 
significant differences, the specificity of this finding is 
evident in various health conditions [49–51].
The data collection was well-executed and a high pro-
portion of the subjects in 2000 study participated also in 
the follow-up study in 2011. Although previously reported 
in other studies [52, 53], there were no significant differ-
ences in continuation in present study between males and 
females. Overall, the adherence to present study (58%) can 
be regarded good and in line with the previous studies, 
especially considering the trend of reduced participation 
in epidemiological studies during the past decades [54, 
55]. Loss to follow-up was also compensated by apply-
ing calibrated weighting scheme and the differences in 
samples were adjusted by weighting the analyses with 
IPW-method. [39] Due to the study design, immigration 
to Finland after year 2000 has not been covered as the 
baseline sample defines characteristics for the weighting 
[26]. Study participants participating in the eye examina-
tion in 2000 were similar in their distribution when com-
pared to those who had complete information from both 
time points.
When examining the association between longitudinal 
changes in HRQoL and VA, we accounted for incidence 
of common comorbidities. We found that 15D and EQ-5D 
were more strongly associated with the declining distance 
VA than with any of the examined incident comorbidities, 
3234 Quality of Life Research (2019) 28:3225–3236
1 3
except musculoskeletal conditions when examining EQ-5D. 
Association between HRQoL and declining near was not as 
large. The absolute impact of Parkinson’s disease on HRQoL 
was somewhat higher than impact of declining distance VA.
Saarni et al. have previously reported impact of various 
health conditions on HRQoL [56]. In their cross-sectional 
analysis, cataract and glaucoma have only marginal effect 
while the impact of macular degeneration is statistically sig-
nificant and 15D-wise clinically important as well. How-
ever, in their analysis, health conditions are implemented 
as ‘averaged’ diseases, regardless of how much their vision 
or functioning is affected by the disease. In this work, we 
reported that longitudinal VA decline however has statis-
tically significant and even clinically important impact on 
HRQoL. Comparing the loss of HRQoL associated with var-
ious health problems helps to put in perspective the poten-
tial impact achievable by the development of treatments for 
these conditions.
There are also potential limitations in our study. We were 
unable to assess the impact of other types of visual impair-
ment, such as diminishing visual field, on HRQoL. The eye 
examination was carried out by a general practitioner, rather 
than an ophthalmologist, which can be considered as a weak-
ness. However, it was necessary due to the large sample size 
and the complex study design. Another limitation was that 
we had to combine comorbidities into rather large groups 
(e.g., heart disease or psychiatric disorder) when estimat-
ing their impact on HRQoL, as new diagnoses during the 
11-year follow-up are scarce for many specific diseases, such 
as psychosis. Moreover, we did not have the data available 
to differentiate disease types or severities, for example, spe-
cific cancer types, and had to account them as homogenous 
groups, regardless of the potential heterogeneity of spe-
cific diseases. Also, in the present analysis, we examined 
the general visual function and did not evaluate impact of 
specific vision-impairing diseases separately. For instance, 
age-related macular degeneration and glaucoma have been 
previously associated with declining QoL [57, 58]. In the 
future analyses it would be beneficial to evaluate and com-
pare HRQoL impact of disease-specific HRQoL impacts 
in longitudinal setting. The long duration of the follow-up 
might also cause problems, as there has been progression 
on the therapies for various conditions. Also, the diagnos-
tics have developed, meaning that a growing proportion of 
diseases are being diagnosed even symptomless.
Concerning EQ-5D and 15D index scores, we included 
only study participants with complete information collected 
in each assessment. The proportion of study participants 
with complete HRQoL data and insufficient VA-data was 
quite low, ranging from 0.4 to 0.8%, and therefore potential 
bias resulted by it is also likely to be low. Taking the loss to 
follow-up into account, it needs to be acknowledged that the 
proportion of study population with complete information 
from both time points is somewhat lower. Even so, the study 
sample remains large (4703 participants) and representa-
tive. Additionally, the study population was predominantly 
Finnish, and the results may not be applicable to other coun-
tries and ethnicities. However, the comparability is some-
what improved by our use of UK time-trade-off weights for 
EQ-5D instead of the Finnish preference weights.
Although the findings of the present study are based on 
large, representative Finnish population-based samples, 
more detailed analyses with large population-based study 
samples are required to validate the generalizability of these 
results into other settings as well. Moreover, additional stud-
ies with over 10 years of follow-up are necessary to ascertain 
the impact of declining vision on HRQoL.
Conclusions
Our findings suggest that declining vision significantly 
affects quality of life even before the diagnosis of severe 
vision loss, visual impairment, or blindness. This encour-
ages developing new or enhancing the existing treatment 
options aiming to improve vision, stop progression of eye 
diseases or at least postpone the onset of visual impairment 
or declining visual acuity, and the associated loss of qual-
ity of life. Regardless of all the treatment options available, 
some patients with declining VA experience problems in 
their daily life. The importance of rehabilitation and social 
services in maintaining good HRQoL is indisputable to 
reduce the functional disability caused by VA loss. This 
study provides HRQoL data comparable to other health 
conditions and changes in them, which helps evaluating the 
best possible allocation of health-care resources.
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